论文部分内容阅读
目的分析利用广州地区儿童急性淋巴细胞白血病2002化疗协作组方案(GZ-ALL-2002)治疗儿童急性淋巴细胞性白血病的结果,并与全国小儿急淋方案治疗做初步比较。方法对1999年-2002年收治的10例初治儿童ALL采用全国小儿急淋方案治疗,对2003年-2008年收治的ALL儿童35例采用GZ-ALL-2002方案进行治疗,评价治疗效果、缓解情况、严重感染并发症及治疗相关死亡等。结果所有研究对象在治疗及回访过程中均未出现死亡患者。利用GZ-ALL-2002方案治疗,长期完全缓解25例(71.4%),复发10例(28.6%),其中SR、MR及HR的EFS分别为83.3%(10/12)、70.0%(14/20)、33.3%(1/3)。GZ-ALL-2002方案中的35例患者相关感染达39例次。利用全国小儿急性淋巴细胞白血病方案进行治疗后,10例患者中长期完全缓解7例(70%),复发3例(30%)。结论 GZ-ALL-2002方案与全国小儿急性淋巴细胞白血病方案的整体治疗效果评判仍需扩大样本范围。
Objective To analyze the results of treatment of acute lymphoblastic leukemia in children with Guangzhou Children’s Acute Lymphoblastic Leukemia and Chemotherapy Cooperative Group (GZ-ALL-2002) and compare with the national pediatric acute rickets treatment. Methods Ten children with ALL who were admitted to our hospital from 1999 to 2002 were enrolled in this study. All the children in ALL from 2003 to 2008 were enrolled in the GZ-ALL-2002 regimen. All patients were evaluated with the treatment effect and remission Condition, serious infection complications and treatment-related deaths. Results All the subjects did not die during the treatment and follow-up visits. The EFS of SR, MR and HR were 83.3% (10/12) and 70.0% (14.0%) in 25 cases (71.4%) and 10 cases (28.6% 20), 33.3% (1/3). 35 patients in the GZ-ALL-2002 regimen were associated with 39 infections. After treatment with the National Pediatric Acute Lymphoblastic Leukemia Program, 7 patients (70%) achieved complete remission in mid and long term, and 3 patients (30%) relapsed in 10 patients. Conclusion GZ-ALL-2002 program and the national pediatric acute lymphoblastic leukemia program evaluation of the overall treatment effect still need to expand the sample range.